The Filing Desk

ImageneBio vs Rallybio

ImageneBio IMA · Rallybio RLYB · Biotechnology

Rallybio reported revenue of $1 million in fiscal 2025, about the same as ImageneBio's $1 million in fiscal 2025. ImageneBio's revenue fell 77.1% in its latest year, and Rallybio's grew 34.9%. ImageneBio had an operating margin of -6056.4%, against -3853.6% at Rallybio.

Side by side

ImageneBioRallybio
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$1M$1M
Revenue growth−77.1%34.9%
Revenue growth a year, last 5 years−38.6%—
Gross margin——
Operating margin−6,056.4%−3,853.6%
Net margin−5,668.6%−1,046.4%
Free cash flow——
Free cash flow margin——
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count303.7%3.4%
Last close$3.98$15.52
P/E at the last close—3.4×
Insider trades, last 12 monthsbought $95,840, sold $17,334—
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ImageneBioRallybio
Operating margin
Percent of revenue
ImageneBioRallybio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ImageneBioRallybio

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ImageneBio and Rallybio pages.